Beyond DS and LGS, soticlestat has been explored as a potential treatment for other DEEs, including chromosome 15q duplication syndrome, cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), and tuberous sclerosis complex. This evidence concerns the gene CDKL5 and Dravet syndrome.